Brianna Wronko-Stevens is a University of Pennsylvania-trained bioengineer who turned a senior design project into HueDx (formerly Group K Diagnostics), a Philadelphia diagnostics company that reads lab-grade results off a color-changing card and a smartphone camera - no lab, no reader, no waiting days. Inspired by an HIV clinic internship at 17, she built a platform to deliver fast, quantitative results to the patients who can least afford to wait. She founded the company in 2017, served as CEO through a 2023 rebrand and raised millions in funding, then stepped into the Chief Scientific Officer seat to focus on the science.
Hiranjith H (also Hiranjith GH) is the Chief Business Officer of Algorithmic Biologics, a Bengaluru-founded deeptech startup that embeds algorithms inside test tubes to make molecular testing dramatically cheaper and faster. Based in the San Francisco Bay Area, he leads the company's commercial operations and US expansion. He spent more than a decade scaling MedGenome's research-services business in the US and earlier built commercialization and analytics strategy for life-sciences clients at Novartis, ZS Associates, and Accenture Management Consulting.
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.
AltPep is a Seattle biotech company spun out of the University of Washington that is building both diagnostic tests and disease-modifying drugs for amyloid diseases such as Alzheimer's and Parkinson's. Its work is anchored on the alpha-sheet, a non-standard protein structure discovered by founder and CEO Valerie Daggett, which forms in the toxic soluble oligomers that appear at the earliest, pre-symptomatic stages of disease. AltPep's SOBA blood test aims to flag those toxic oligomers years before symptoms, while its SOBIN peptide therapeutics are designed to neutralize them.
Lifeforce is a personalized health optimization and longevity-medicine platform that pairs at-home blood diagnostics measuring 40-50+ biomarkers with telehealth consults, a personal health coach, and tailored interventions including supplements, hormone protocols, and prescription medication. Co-founded in 2021 by Tony Robbins, Dr. Peter Diamandis, Dugal Bain-Kim, and Joel Jackson, the company aims to help people in midlife take a proactive, data-driven approach to feeling and functioning better rather than waiting for disease to show up.
Dr. E. Robert (Bob) Wassman is Chief Medical Officer and Executive Vice President of Clinical Development at MARAbio, a Utah-based diagnostics company building a maternal blood test to identify an autoimmune subtype of autism. A board-certified pediatrician and medical geneticist with more than 40 years in the field, he has served as chief medical officer for a long roster of genetic-testing pioneers including Genzyme Genetics, Ambry Genetics, Rosetta Genomics and Good Start Genetics, repeatedly turning frontier laboratory technology into clinical service across reproductive medicine, cancer, and neurodevelopmental disability.
Charles R. Bridges, M.D., Sc.D., is Executive Vice President and Chief Scientific Officer at CorVista Health, where he leads the science behind a machine-learning cardiac diagnostic platform. A cardiac surgeon turned engineer-executive, he holds an A.B. in applied physics from Harvard, an M.D. from Harvard Medical School (which he entered at 18), and both an M.S. in electrical engineering and a D.Sc. in chemical engineering from MIT. He was the first African American full professor of surgery at the University of Pennsylvania, served as a technology chief at Johnson & Johnson's Janssen, and in 2022 was elected to the U.S. National Academy of Engineering. His record spans 175 peer-reviewed publications, 15 patents, and more than $10 million in continuous NIH funding.
MARAbio is a Salt Lake City precision-immunology company that built the first-ever blood test to identify Maternal Autoantibody Related Autism (MARA), a biological subtype of autism caused by a mother's own IgG autoantibodies crossing the placenta and binding fetal brain proteins. Founded on more than two decades of research by Dr. Judy Van de Water at the UC Davis MIND Institute, the company's MAR-Autism test screens mothers for specific autoantibody combinations linked to autism risk, and the company is now extending the science toward therapeutics that could neutralize those antibodies before they reach a developing brain.
Numen (formerly Cleancard) is a San Francisco biotech building rapid at-home cancer screens that read like a pregnancy test. By combining synthetic biology, machine learning, and computer vision, its platform detects multiple cancer biomarkers from a single urine sample in about 30 minutes, with no lab machinery required. Founded by Rhodes Scholars Thomas Carroll and Luca Springer, the company's first screens target prostate, bladder, and ovarian cancer, with a mission to drive cancer mortality toward zero.
Progentec Diagnostics is an Oklahoma City company building blood-based biomarker tests and digital health tools for autoimmune diseases, starting with lupus. Its lead product, the aiSLE DX Flare Risk Index, uses an 11-biomarker algorithm to predict a lupus flare up to 12 weeks before it happens, giving rheumatologists a chance to intervene early. Spun out of research tied to the Oklahoma Medical Research Foundation, the company pairs lab science with patient-facing tools like the LupusCorner community to move autoimmune care from reactive to proactive.
Fred Turner is the founder and CEO of Curative, a health-insurance company built on the radical premise of no copays, no deductibles, and no cost-sharing for in-network care. A British biochemist who dropped out of Oxford, he won the UK's Young Engineer of the Year at 17 for building a PCR machine to study his brother's red hair, founded cattle-genetics and diagnostics startups, then pivoted Curative into one of the largest COVID-19 testing providers in the United States before reinventing it as a health plan. He says his goal is to put his own company out of business by keeping members healthy.
Linh Hoang, MD, PhD, is the Chief Executive Officer of HistoWiz, the New York based digital pathology company building PathologyMap, a platform that automates histology and connects researchers to top pathologists on demand. A physician-scientist turned operator, he trained at the University of Pennsylvania, cut his teeth at Boston Consulting Group, and ran businesses at Thermo Fisher and PerkinElmer before leading two diagnostics companies as CEO, Boston Microfluidics and its successor Weavr Health, ahead of joining HistoWiz in October 2022.
Luca Springer is the co-founder and CEO of Numen (formerly Cleancard), a San Francisco synthetic-biology company building rapid at-home diagnostic tests that read biomarkers from a urine sample in about 30 minutes. A 2016 German Rhodes Scholar who once planned a career in European politics, he traded the policy track for the lab bench, pairing degrees in computer science and global governance from Oxford with a dual BA from Columbia and Sciences Po. He started the company in 2021 with fellow Rhodes Scholar Thomas Carroll, went through Y Combinator's Summer 2023 batch, and has raised roughly $5.1M to make lab-grade screening as simple as a pregnancy test.
Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.
Robert K. Weigle is a medical device and diagnostics executive with more than 25 years of experience taking healthcare products from pre-clinical research to commercial launch. He is CEO of NOW Diagnostics, an independent board member of Tenon Medical, and a former entrepreneur-in-residence at DigitalDx Ventures. He led Benvenue Medical as CEO for over a decade, raising more than $200 million and launching spine devices in two markets, and later ran saliva-based diagnostics companies focused on cancer detection. His career spans Fortune 500 names like Johnson & Johnson and Baxter as well as a string of venture-backed startups.
Evvy is a precision women's health company building the first AI-powered vaginal healthcare platform around a CLIA-certified, at-home metagenomic vaginal microbiome test. Founded in 2021 by Stanford alums Priyanka Jain and Laine Bruzek, Evvy pairs state-of-the-art testing that screens for 700+ bacteria and fungi with clinician-reviewed results, personalized prescription treatment, and one-on-one health coaching. By generating one of the largest datasets on female biomarkers, Evvy aims to close the gender health gap - starting with conditions like bacterial vaginosis that have been chronically under-researched.
Valerie Daggett is a University of Washington bioengineering professor turned biotech founder who spent three decades running the world's largest collection of protein-folding simulations, stumbled onto a structure nature was not supposed to make, and built a company around it. As founder and CEO of Seattle-based AltPep, she is commercializing the alpha-sheet: a strange protein geometry her lab predicted on a computer before anyone confirmed it in a test tube. Her SOBA-AD blood test, which spots toxic amyloid oligomers years before symptoms, earned FDA Breakthrough Device Designation and put her at the front of the race to catch Alzheimer's early.
Tom Schoenherr is CEO of Diagnostics at Tempus AI, the publicly traded precision-medicine company. He previously ran Ambry Genetics as CEO from 2021 to 2025, steering it through a definitive agreement to be acquired by Tempus. He has spent more than 25 years inside molecular diagnostics, with prior leadership stints at Counsyl, Quest Diagnostics, Siemens Healthcare, Abbott Diagnostics, and Omada Health.
Neuron7.ai is a Santa Clara-based enterprise AI company building service resolution intelligence - software that helps technicians, agents, and customers diagnose and fix complex products in seconds rather than days. Its platform fuses unstructured manuals, ticket histories, telemetry, and expert know-how into guided, real-time answers used by Fortune 1000 service organizations across medical devices, telecom, industrial equipment, and high tech.
Julián Ríos Cantú is the co-founder and CEO of Eden, the leading cloud-native radiology operating system in Latin America. Motivated by his mother's battle with breast cancer, he began building health technology at age 16, went on to become the youngest-ever winner of the Global Student Entrepreneur Awards at 18, earned a Thiel Fellowship, and went through Y Combinator in 2018. Today, Eden processes over 13 million diagnostic studies annually across 18 countries for more than 2,200 medical institutions, backed by Sierra Ventures, Khosla Ventures, Kaszek, and notable angel investors including Leonardo DiCaprio, Ashton Kutcher, and Tony Robbins.
Beckie Robertson is co-founder and general partner at Versant Ventures, a San Francisco-based venture capital firm focused on biotechnology and drug discovery. A chemical engineer by training, she has spent decades backing early-stage medical device and diagnostics companies, with prior operating roles at Chiron Diagnostics, Lifescan, and Egis. She currently serves as vice chair of the Cornell Board of Trustees and was awarded the Cornell Duffield Engineering Distinguished Alumni Award in April 2026.
Mammoth Biosciences is a Brisbane, California biotechnology company co-founded by Nobel laureate Jennifer Doudna that develops ultracompact CRISPR systems for both in vivo gene-editing therapeutics and rapid molecular diagnostics. Its proprietary toolbox of small Cas enzymes (including Cas14 and CasΦ) powers therapeutic partnerships with Regeneron, Vertex and Bayer, while the DETECTR platform brings CRISPR-based disease detection out of the central lab.
Zack Scott is a General Partner and Co-Head of the Healthcare Investment Team at Norwest Venture Partners, one of Silicon Valley's most active multi-stage venture capital firms. A rare combination of clinically trained physician and seasoned investor, Scott brings an MD from UT Health San Antonio and an MBA from Duke's Fuqua School of Business to a career that spans surgical residency, healthcare venture investing at Burrill & Company, co-founding Revelation Partners (a healthcare-focused secondary investment firm), and now leading healthcare deals at Norwest. His portfolio includes companies like ShiraTronics, SetPoint Medical, Cytovale, and Galvanize Therapeutics, with notable exits including Omada Health's IPO and acquisitions by Stryker, Zoll Medical, Abbott, and Olympus.
Kim Kelderman is the President and CEO of Bio-Techne Corporation, a global life science tools and diagnostics company headquartered in Minneapolis, Minnesota. With over 30 years of healthcare and life sciences experience, Kelderman rose through the ranks at Bio-Techne after joining in 2018 to lead the Diagnostics and Genomics segment, where he doubled the spatial biology business and commercialized the ExoDx Prostate test. A native of the Netherlands educated at Hogeschool Heerlen and Columbia Business School, he previously held executive roles at Thermo Fisher Scientific and Becton Dickinson. He became CEO on February 1, 2024, succeeding Chuck Kummeth.
Alec Ford is the chief executive of Karius, a Redwood City genomics-diagnostics company that reads microbial cell-free DNA from a single tube of blood to identify more than a thousand pathogens. He took the job in October 2020 and led the company through a $100M Series C in May 2024.
Andrew Quong is President and CEO of InterVenn Biosciences, a South San Francisco-based precision diagnostics company unlocking the human glycoproteome through AI-powered platforms. With a PhD in Physics and over 30 years spanning national laboratories, academia, and biotech, Quong bridges the physical and computational sciences with clinical medicine. He led InterVenn's development of GlycoKnow Ovarian, a non-invasive blood-based liquid biopsy test for distinguishing ovarian cancer from benign masses, and has steered the company through key commercialization milestones including a $201M Series C raise in 2021.
Trevor Martin is the co-founder and CEO of Mammoth Biosciences, the CRISPR company he built alongside Nobel laureate Jennifer Doudna and two of her graduate students. A Princeton-trained computational biologist who earned his PhD at Stanford, Martin turned a cold email to Doudna into a $465M-funded platform company developing ultracompact CRISPR systems - including NanoCas, the first efficient extrahepatic gene editor - aimed at permanently curing genetic diseases.